The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback